ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products

Part 4 – Biological Products
COVID-19 Vaccines

COVID-19 mRNA Vaccine COMIRNATY® (Pfizer-BioNTech) 5-11 Years of Age
A minor revision under BOOSTER DOSES has been made to align with the COVID-19 Vaccine Eligibility page.

Please remove page numbers: 1-5 dated June 2023
Please add new page numbers: 1-5 dated July 2023

COVID-19 mRNA Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech) Adult/Adolescent

- Content under INDICATIONS has been revised as this vaccine is now approved for use in the primary series by Health Canada. The associated footnote indicating informed consent should include a discussion that the vaccine had not yet been approved for use in the primary series has been removed.
- The Health Canada authorized schedule for the primary series has been added to a footnote; however, the recommended interval between dose 1 and 2 is 8 weeks and is associated with optimal vaccine effectiveness.

Please remove page numbers: 1-5 dated June 2023
Please add new page numbers: 1-5 dated July 2023
COVID-19 Vaccine COMIRNATY® Bivalent (Pfizer-BioNTech) 5-11 Years of Age

- Content under INDICATIONS has been revised as this vaccine is now approved for use in the primary series by Health Canada. The associated footnote indicating informed consent should include a discussion that the vaccine had not yet been approved for use in the primary series has been removed.
- The Health Canada authorized schedule for the primary series has been added to a footnote; however, the recommended interval between dose 1 and 2 is 8 weeks and is associated with optimal vaccine effectiveness.
- Content under BOOSTER DOSES has been revised to indicate that a bivalent COVID-19 mRNA vaccine is recommended 6 months after the primary series.

Please remove page numbers: 1-5 dated June 2023
Please add new page numbers: 1-5 dated July 2023

COVID-19 Vaccine SPIKEVAX™ (Moderna) 6 months – 5 Years of Age

Content under BOOSTER DOSES has been clarified to include the booster dose recommendation for individuals 5 years of age and older.

Please remove page numbers: 1-4 dated May 2023
Please add new page numbers: 1-4 dated July 2023
If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Immunization Programs and Vaccine Preventable Diseases Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry

BC Ministry of Health,
Communicable Disease Prevention and Control,
Population & Public Health Division:

Bethany McMullen
Director, Immunizations

Brian Sagar
A/Executive Director